Kyowa Kirin Co., Ltd. is a Japan-based specialty biopharmaceutical company focused on the research, development, manufacturing, and commercialization of prescription medicines, with an emphasis on biologics and targeted therapies. Headquartered in Tokyo, the company operates globally across Japan, Asia, Europe, and North America. Kyowa Kirin originated from the merger of Kyowa Hakko’s pharmaceutical business and Kirin Pharma, and later adopted its current name after operating as Kyowa Hakko Kirin.
The company’s R&D centers on therapeutic areas such as oncology, nephrology, immunology/inflammation, and rare diseases. Kyowa Kirin is known for expertise in antibody engineering and bioprocess development, supporting the development of monoclonal antibodies and other advanced biologics. Its activities span early discovery through clinical development and commercial supply, with a track record of partnerships and licensing agreements to advance pipeline programs and broaden market access.
Also known as Kyowa Hakko Kirin.
VESALIUS‑CV subgroup shows evolocumab lowers first major cardiovascular events and LDL‑C; real‑world GLP‑1 persistence is low, curbing potential benefits.
Approved with bortezomib+dexamethasone for adults after ≥1 prior line; DREAMM‑7: 3x PFS (36.6 vs 13.4m) and 42% lower death risk; outpatient ADC; ocular AEs manageable.
VESALIUS‑CV subgroup (3,655 high‑risk diabetics without known atherosclerosis) showed a 31% reduction in first major CV events vs placebo; median LDL‑C 44 mg/dL over ~4.8 years.
Boehringer gains exclusive rights to develop a small molecule for autoimmune diseases, with potential payments to Kyowa Kirin up to €640 million.
